Reaction Details Report a problem with these data
Target
Galectin-3
Ligand
BDBM468292
Substrate
n/a
Meas. Tech.
Evaluation of Kd Values
Kd
64.0±n/a nM
Citation
Leffler, H; Nilsson, U; Zetterberg, F Hybrid galactoside inhibitor of galectins US Patent US10800804 Publication Date 10/13/2020
More Info.:
Target
Name:
Galectin-3
Synonyms:
LEG3_HUMAN | LGALS3 | MAC2
Type:
Enzyme
Mol. Mass.:
26156.54
Organism:
Homo sapiens (Human)
Description:
P17931
Residue:
250
Sequence:
MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPPGAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI
Inhibitor
Name:
BDBM468292
Synonyms:
3-(9-anthracene carboxamide)-3,3′-Dideoxy-3-[4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-1,1′-sulfanediyl-di-β-D-galactopyranoside | US10800804, Example S20a
Type:
Small organic molecule
Emp. Form.:
C39H43FN4O9S
Mol. Mass.:
762.844
SMILES:
CC(C)(C)c1c2ccccc2c(C(=O)NC2C(O)[C@@H](CO)OC(S[C@@H]3OC(CO)[C@H](O)[C@@H](C3O)n3cc(nn3)-c3cccc(F)c3)[C@@H]2O)c2ccccc12 |r|